SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)

N/AActive Not RecruitingNCT04470934

B. Braun Melsungen AG1,302 enrolled

Overview

The aim of the study is to assess continued safety and efficacy of the SeQuent® SCB. The product under investigation will be used in routine clinical practice according to the latest European Society of Cardiology (ESC) guidelines and according to the Instructions for Use (IFU). Those data that are obtained in routine clinical use will be documented in the Case Report Form (CRF).

The objective of the study is to assess the continued safety and efficacy of SeQuent® SCB for the treatment of "real world" de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts. Study goals are based on non-inferiority for Drug-Coated Balloon (DCB) compared to Paclitaxel-Coated Balloon (PCB) and Dru-eluting Stents (DES) (historical data) with 80% power. Primary and secondary outcome variables are international accepted parameters in stent-trials, which sufficiently describe the efficacy and safety of the investigated device and allow clinical conclusions. Additional attention will be paid to those patients who received, by observation, a shortened dual antiplatelet therapy (DAPT). The aim of the study is to assess the safety and efficacy of the SeQuent® SCB in the treatment of coronary artery disease with reference vessel diameters between ≥ 2 mm and ≤ 4 mm with suitable lesion lengths. There is no limitation of lesion lengths. In case the lesion is longer than 34 mm, more than one stent needs to be used.

Study Type

OBSERVATIONAL

Enrollment

1,302

Conditions

Coronary Artery Disease Myocardial Ischaemia

Interventions

SeQuent® SCB drug-coated balloon catheterDEVICE

treatment of coronary artery disease with SeQuent® SCB of "real world" de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All common significant coronary lesions * Target lesion length \>34mm need to be covered with at least 2 devices * Patients eligible for this study must be at least 18 years of age * The patient must fulfil the standard recommendations for percutaneous coronary intervention (PCI), based on the last ESC recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment Exclusion Criteria: * Intolerance to sirolimus * Allergy to components of the coating * Pregnancy and lactation * Complete occlusion of the treatment vessel because of an unsuccessfully re-canalized * Cardiogenic shock * Risk of an intraluminal thrombus * Hemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anti-coagulation therapy * Surgery shortly after myocardial infarction with indications of thrombus or poor coronary flow behavior * Severe allergy to contrast media * Lesions which are untreatable with PCI or other interventional techniques * Patients with an ejection fraction of \< 30 % * Vascular reference diameter \< 2.00 mm * Treatment of the left stem (first section of the left coronary artery) * Indication for a bypass surgery * Contraindication for whichever accompanying medication is necessary

Locations (1)

Universitätsklinikum Jena

Jena, Thuringia, Germany

Outcomes

Primary Outcomes

Target Lesion Failure (TLF)

Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR).

Time frame: at 12 months

Secondary Outcomes

Target Lesion Failure (TLF)

Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR).

Time frame: at 24 months

ischemia driven target lesion revascularization (TLR)

Time frame: at 12 months

ischemia driven target lesion revascularization (TLR)

Time frame: at 24 months

all-cause death, cardiac death

Time frame: at 12 months

all-cause death, cardiac death

Time frame: at 24 months

all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI)

Time frame: at 12 months

all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI)

Time frame: at 24 months

major adverse coronary event (MACE)

major adverse coronary event (MACE): defined as composite of cardiovascular death, myocardial infarction or ischemia-driven target lesion revascularization

Time frame: at 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.